<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-156049</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Clinical guidelines for infantile-onset Pompe disease</dc:title>
<dc:description xml:lang="en">Infantile-onset Pompe disease has a fatal prognosis in the short term unless it is diagnosed at an early stage and enzyme replacement therapy is not started as soon as possible. A group of specialists from different disciplines involved in this disease have reviewed the current scientific evidence and have drawn up an agreed series of recommendations on the diagnosis, treatment and follow-up of patients. We recommend establishing enzyme treatment in any patient with symptomatic Pompe disease with onset within the first year of life, with a clinical and enzymatic diagnosis, and once the CRIM (cross-reactive immunological material) status is known (AU)</dc:description>
<dc:creator>Manrique Rodríguez, Silvia</dc:creator>
<dc:creator>Pascual Pascual, Samuel I</dc:creator>
<dc:creator>Ley, Miriam</dc:creator>
<dc:creator>Fernández Llamazares, Cecilia M</dc:creator>
<dc:creator>Medrano López, Constancio</dc:creator>
<dc:creator>Villalobos Pinto, Enrique</dc:creator>
<dc:creator>Nascimiento, Andrés</dc:creator>
<dc:creator>Martínez Moreno, Mercedes</dc:creator>
<dc:creator>Blasco Alonso, Javier</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La enfermedad de Pompe infantil tiene un pronóstico fatal a corto plazo si no se diagnostica precozmente ni se inicia un tratamiento enzimático sustitutivo lo antes posible. Un grupo de especialistas de las diferentes disciplinas involucradas en esta enfermedad ha revisado la evidencia científica actual y ha elaborado por consenso una serie de recomendaciones para el diagnóstico, el tratamiento y el seguimiento de los pacientes. Se recomienda instaurar tratamiento enzimático en todo paciente con enfermedad de Pompe sintomática de comienzo en el primer año de vida, con diagnóstico clínico y enzimático, y una vez conocido el estado CRIM (material inmunológico con reactividad cruzada) (AU)</dc:description>
<dc:source>Rev Neurol;63(6): 269-279, 16 sept., 2016. tab, graf</dc:source>
<dc:identifier>ibc-156049</dc:identifier>
<dc:title xml:lang="es">Guía clínica de la enfermedad de Pompe infantil</dc:title>
<dc:subject>^d4871^s22073</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d24392^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d24392^s22011</dc:subject>
<dc:subject>^d24392^s22033</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d520^s22073</dc:subject>
<dc:subject>^d9327^s22016</dc:subject>
<dc:subject>^d9327^s22047</dc:subject>
<dc:subject>^d38340</dc:subject>
<dc:subject>^d30291</dc:subject>
<dc:subject>^d520^s22078</dc:subject>
<dc:subject>^d30602^s22048</dc:subject>
<dc:subject>^d9327^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201609</dc:date>
</metadata>
</record>
</ibecs-document>
